| Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205 M Puhr, J Hoefer, G Schäfer, HHH Erb, SJ Oh, H Klocker, I Heidegger, ... The American journal of pathology 181 (6), 2188-2201, 2012 | 269 | 2012 |
| ZEB 1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat S Meidhof, S Brabletz, W Lehmann, BT Preca, K Mock, M Ruh, J Schüler, ... EMBO molecular medicine 7 (6), 831-847, 2015 | 233 | 2015 |
| Interleukin-6: a multifunctional targetable cytokine in human prostate cancer Z Culig, M Puhr Molecular and cellular endocrinology 360 (1-2), 52-58, 2012 | 203 | 2012 |
| The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy M Puhr, J Hoefer, A Eigentler, C Ploner, F Handle, G Schaefer, J Kroon, ... Clinical Cancer Research 24 (4), 927-938, 2018 | 162 | 2018 |
| Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo L Gu, P Vogiatzi, M Puhr, A Dagvadorj, J Lutz, A Ryder, S Addya, ... Endocrine-related cancer 17 (2), 481, 2010 | 156 | 2010 |
| Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells L Ippolito, A Marini, L Cavallini, A Morandi, L Pietrovito, G Pintus, ... Oncotarget 7 (38), 61890, 2016 | 133 | 2016 |
| The role of epithelial–mesenchymal transition drivers ZEB 1 and ZEB 2 in mediating docetaxel‐resistant prostate cancer K Hanrahan, A O'Neill, M Prencipe, J Bugler, L Murphy, A Fabre, M Puhr, ... Molecular oncology 11 (3), 251-265, 2017 | 132 | 2017 |
| EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205 P Massoner, T Thomm, B Mack, G Untergasser, A Martowicz, K Bobowski, ... British journal of cancer 111 (5), 955-964, 2014 | 116 | 2014 |
| Interleukin-6 and prostate cancer: Current developments and unsolved questions Z Culig, M Puhr Molecular and cellular endocrinology 462, 25-30, 2018 | 115 | 2018 |
| In vitro model systems to study androgen receptor signaling in prostate cancer N Sampson, H Neuwirt, M Puhr, H Klocker, IE Eder Endocr Relat Cancer 20 (2), R49-64, 2013 | 114 | 2013 |
| Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways M Puhr, FR Santer, H Neuwirt, M Susani, JA Nemeth, A Hobisch, ... Cancer research 69 (18), 7375-7384, 2009 | 100 | 2009 |
| PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21 J Hoefer, G Schäfer, H Klocker, HHH Erb, IG Mills, L Hengst, M Puhr, ... The American journal of pathology 180 (5), 2097-2107, 2012 | 91 | 2012 |
| miR-22 and miR-29a are members of the androgen receptor cistrome modulating LAMC1 and Mcl-1 in prostate cancer L Pasqualini, H Bu, M Puhr, N Narisu, J Rainer, B Schlick, G Schäfer, ... Molecular endocrinology 29 (7), 1037-1054, 2015 | 85 | 2015 |
| Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent … H Neuwirt, M Puhr, FR Santer, M Susani, W Doppler, G Marcias, V Rauch, ... The American journal of pathology 174 (5), 1921-1930, 2009 | 85 | 2009 |
| Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer I Bellezza, H Neuwirt, C Nemes, IT Cavarretta, M Puhr, H Steiner, ... The American journal of pathology 169 (6), 2199-2208, 2006 | 80 | 2006 |
| Inflammation, microbiota, and prostate cancer M Puhr, A De Marzo, W Isaacs, MS Lucia, K Sfanos, ... European urology focus 2 (4), 374-382, 2016 | 67 | 2016 |
| Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer J Kroon, M Puhr, JT Buijs, G Van Der Horst, DM Hemmer, KA Marijt, ... Endocrine-related cancer 23 (1), 35-45, 2016 | 66 | 2016 |
| Oligomeric proanthocyanidin complexes (OPC) exert anti‐proliferative and pro‐apoptotic effects on prostate cancer cells H Neuwirt, MC Arias, M Puhr, A Hobisch, Z Culig The Prostate 68 (15), 1647-1654, 2008 | 66 | 2008 |
| Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide J Hoefer, M Akbor, F Handle, P Ofer, M Puhr, W Parson, Z Culig, ... Oncotarget 7 (37), 59781, 2016 | 64 | 2016 |
| Inhibition of Nox4‐dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal‐mediated protumorigenic interactions N Sampson, E Brunner, A Weber, M Puhr, G Schäfer, C Szyndralewiez, ... International journal of cancer 143 (2), 383-395, 2018 | 62 | 2018 |
